Medical Facilities (31F) Q2 2026 Earnings Report

The call presented a generally positive operational and financial update: revenue, income from operations, and EBITDA all grew year-over-year, liquidity is strong with no corporate-level debt, and shareholder returns remain substantial via buybacks. However, the company faces notable volume softness in certain categories (inpatient, observation, pain management), and operating costs rose materially, which temper the outlook. Overall the positives—top-line and profit growth, strong cash position, and committed capital returns—outweigh the headwinds from volume mix and expense pressures.

Management provided limited forward-looking numeric guidance, instead emphasizing balance-sheet flexibility and a continued priority on returning capital to shareholders: they repurchased ~1.34 million shares for $17.1M in Q2 (≈1.66M for $21M in H1) and have since fully used the current NCIB limit of ≈1.81M shares, contributing to a cumulative CAD 218M returned since Q3 2022; cash at quarter end was $64.1M (including $58M at corporate), consolidated net working capital was $65.2M (vs. $54.0M at year-end Dec.; cash then $43.4M), and the company has no corporate-level bank debt after paying off its credit facility in 2024. Operational context for that guidance included revenue of $63.1M (up 7.8%), income from operations of $9.6M (up 9.4%), EBITDA of $12.5M (up 7.1%), operating expenses up $3.8M (7.6%) with drugs & supplies +12.5%, salaries & benefits +6.4% and G&A +3.8%; surgical volume was down 2.3% (essentially flat excluding low‑margin dental), outpatient +0.9%, inpatient -12.5%, observation -9.1%, and pain management -19.9% (with new pain and orthopedic physicians joining in September), and management said it will continue supporting hospitals while evaluating the most efficient ways to return capital.